Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
BAP1 expression marks prognosis in advanced ccRCC
da Costa WH et al. Urol Oncol. 2018 Nov 13. doi: 10.1016/j.urolonc.2018.10.017
Key clinical point: Metastatic clear cell renal cell carcinoma tissue expression of BAP1 is a marker for better overall and progression-free survival.
Major finding: The 5-year overall OS rate was 53.2% for patients with BAP1-positive metastases versus 35.1% for those with BAP1-negative tissues (P = .004).
Study details: A retrospective analysis of tumor samples from 124 patients with metastatic clear cell renal cell carcinoma and 38 patients with paired primary tumor and metastases samples.
Disclosures: No funding source or author disclosures were reported.
Citation:
da Costa WH et al. Urol Oncol. 2018 Nov 13. doi: 10.1016/j.urolonc.2018.10.017.